Ventracor chalks up first revenues

By Ruth Beran
Tuesday, 20 September, 2005

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.

The company previously indicated it would reach the milestone before the end of 2005.

Scientists 'reprogram' tumour-supporting immune cells

The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...

Existing medicines could help treat deadly childhood dementia

Australian researchers have identified several existing TGA‑approved medicines that could help...

Statins reduce heart attack and stroke risk in older people

It has previously been unclear whether statins were effective in reducing heart attack and stroke...

Content from other channels on our network

Operational cost reduction in automation: choosing the right automation technology to reduce OPEX

New wastewater facility opens in Western Sydney

Pope Packaging completes Adelaide facility expansion

Victoria opens new training program round to address skills gaps

Bega Group reduces emissions with rooftop solar

Qld Govt backs new resource recovery event

World record set for large-scale perovskite PV efficiency

Can wastewater algae be used in manufacturing?

Intelligent sensor detects petroleum leaks to prevent water contamination

$3m investment in microgrids for Far West communities

How effective are ML algorithms in ICU mortality predictions?

Doctors' inaugural Aged Care Report Card reveals "failures" across the sector

Top 5 insights into why older Australians stop eating well at home

Trusted Knowledge for Clinical Practice and Education: Supporting Australia's Health Workforce Through Change

From supplier to solutions partner: how healthcare is evolving